Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aytu BioPharmaAYTU -0.92%42 5-Year Yield-on-Cost % is 0.00 as of Jul. 22, 2026. GuruFocus rates AYTU with a GF Score™ of 42/100 and a GF Value™ of $0.86 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 513 Drug Manufacturers companies, Aytu BioPharma ranks worse than 194931.58% on this metric.
Aytu BioPharma's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for Aytu BioPharma's 5-Year Yield-on-Cost % or its related term are showing as below:
AYTU's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.29 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Aytu BioPharma 5-Year Yield-on-Cost % Related Terms
AYTU vs TXMD, CPHI, RMTI: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Aytu BioPharma's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aytu BioPharma 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aytu BioPharma's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Aytu BioPharma's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Aytu BioPharma is calculated as
Aytu BioPharma (AYTU) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 22, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Aytu BioPharma and its competitors. According to the industry distribution chart, Aytu BioPharma ranks #999999 out of 513 companies in the Drug Manufacturers industry.
Is Aytu BioPharma's 5-Year Yield-on-Cost % too high?
Aytu BioPharma's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Aytu BioPharma ranks #999999 out of 513 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Aytu BioPharma has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aytu BioPharma's 5-Year Yield-on-Cost % compare to TXMD and CPHI?
According to the Drug Manufacturers industry distribution chart, Aytu BioPharma ranks #999999 out of 513 companies for 5-Year Yield-on-Cost %. This places Aytu BioPharma in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.29, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Aytu BioPharma and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aytu BioPharma's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aytu BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Aytu BioPharma (AYTU) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.86, compared to a current price of $2.16 — trading 151.2% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Aytu BioPharma's overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Aytu BioPharma (AYTU), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aytu BioPharma (AYTU) Overvalued in 2026?
Based on GuruFocus' analysis, Aytu BioPharma stock appears to be overvalued.
The current stock price of $2.16 is trading 151.2% above its estimated GF Value™ of $0.86.
GuruFocus considers Aytu BioPharma to be Significantly Overvalued.
Key valuation signals for AYTU:
5-Year Yield-on-Cost %: 0.00
GF Value™: $0.86 vs. price of $2.16 (151.2% above fair value)
No single metric tells the full story. See the AYTU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
42GF Score
Get the complete analysis for AYTU
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AYTU has been successfully added to your 
